{
    "2018-02-26": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Lilly breast cancer drug wins expanded U.S. approval",
                "features": {
                    "keywords": [
                        "Lilly",
                        "breast cancer",
                        "drug",
                        "expanded",
                        "U.S.",
                        "approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer",
                "features": {
                    "keywords": [
                        "Lilly",
                        "FDA",
                        "Verzenio",
                        "Advanced Breast Cancer"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Eli Lilly Announces Additional FDA Approval For Verzenio - Quick Facts",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "FDA",
                        "Verzenio"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Radius Health (RDUS) to Disappoint Investors in Q4 Earnings?",
                "features": {
                    "keywords": [
                        "Radius Health",
                        "RDUS",
                        "Q4 Earnings",
                        "Disappoint"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-02-26",
                "original_text": "Health Care Sector Update for 02/26/2018: ACHN, OBSV, EGRX, LLY, CNC",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Sector Update",
                        "ACHN",
                        "OBSV",
                        "EGRX",
                        "LLY",
                        "CNC"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Johnson & Johnson’s Neuroscience Segment in 2017",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Neuroscience",
                        "Segment",
                        "2017"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Trulicity",
                        "SGLT-2",
                        "Blood Sugar",
                        "Type 2 Diabetes"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Eli Lilly Reports New Data From Trulicity Phase 3b Study - Quick Facts",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Trulicity",
                        "Phase 3b Study"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}